Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

RegulatoryCardiovascularMedical DevicesSafety Signal

Abiomed and Oscor Warn of Catheter Introducer Leakage Risk

The reported leakage risk in catheter introducers from Abiomed and Oscor poses significant safety concerns that could lead to regulatory scrutiny and impact market perception. Portfolio and strategy teams must evaluate risk management and communication strategies to mitigate potential fallout.

Published: June 19, 2026
Updated: June 19, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiovascular / Medical Devices
Asset: Abiomed
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Asset

Abiomed

Indication

Cardiovascular / Medical Devices

Status

Under Review

Signal Score

8.4

Signal assessment

Signal strength

high

Confidence level

high

Signalhigh
Confidencehigh

Strategic implication

The reported leakage risk in catheter introducers from Abiomed and Oscor poses significant safety concerns that could lead to regulatory scrutiny and impact market perception. Portfolio and strategy teams must evaluate risk management and communication strategies to mitigate potential fallout.

Why it matters

The reported leakage risk in catheter introducers from Abiomed and Oscor poses significant safety concerns that could lead to regulatory scrutiny and impact market perception. Portfolio and strategy teams must evaluate risk management and communication strategies to mitigate potential fallout.

What changed

Safety Signal

Analysis

Abiomed and Oscor reported a potential leakage issue in their introducer sheaths that may lead to increased access-site bleeding.

The reported leakage risk in catheter introducers from Abiomed and Oscor poses significant safety concerns that could lead to regulatory scrutiny and impact market perception. Portfolio and strategy teams must evaluate risk management and communication strategies to mitigate potential fallout.

Monitor for further regulatory actions or recalls related to this issue, as well as any competitor responses.

Related companies & assets

Assets

  • Abiomed →
  • Oscor →

Sources & Humanexa intelligence

Source links

  • Abiomed and Oscor Warn of Catheter Introducer Leakage Risk ↗

Related Humanexa pages

  • Abiomed and Oscor Warn of Catheter Introducer Leakage Risk →

Related signals

Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

Alcon Labs

Asset

Fluorescite

Indication

Ophthalmology / Diagnostic Agent

Status

Approved

Signal Score

8.2

Regulatoryhigh signal

FDA Approves Supplement for Fluorescite by Alcon Labs

The FDA has approved a supplemental application for Fluorescite, which contains fluorescein sodium.

June 21, 2026Read signal →
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

GSK

Asset

Depemokimab

Indication

Immunology / IL-5

Status

Approved

Signal Score

8.2

Regulatoryhigh signal

FDA Accepts Supplement Application for Depemokimab by GlaxoSmithKline

The FDA has accepted the supplemental application for BLA761458, a biologic from GlaxoSmithKline.

June 21, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.